1 January 2007 in Clinical Imaging
31 October 2022 in Japanese Journal of Radiology
1 January 2022 in Turkish Neurosurgery
AIM: To report our experience with the 2.5-mm Surpass EvolveTM flow diverter (FD) in the treatment of distal small cerebral artery aneurysms.MATERIAL and METHODS: This study included 41 patients with 52 aneurysms. Clinical and radiological records and procedural and follow-up outcomes were reviewed retrospectively.RESULTS: The aneurysm morphology was saccular in 45 patients, dissecting in five patients, and fusiform in two patients. Fifty-two aneurysms were treated with 41 Surpass Evolve FDs. The mean diameters of the proximal and distal parent arteries were 2.56 and 2.17 mm, respectively. The mean duration of follow-up was 16.2 +/- 6.6 (6-28) months. Four (10%) patients had acute subarachnoid hemorrhage. In the same session, two patients with two tandem aneurysms and one patient with four tandem aneurysms were treated using a single FD. Intraprocedural hemorrhage and femoral artery pseudoaneurysm occurred in two patients during the procedure. Digital subtraction angiography was performed on 38/41 (92%) patients with 47/52 (88%) having aneurysms. Complete occlusion (OKM D) was observed in 39/47 (82%) aneurysms, and near complete-complete occlusion (OKM C-D) was observed in CONCLUSION: Endovascular treatment of distal cerebral artery aneurysms with the 2.5-mm Surpass EvolveTM FD provides a high rate of aneurysm occlusion with low periprocedural complications, even in ruptured and tandem aneurysms.
24 January 2023 in Balkan Medical Journal
Currently, unilateral clinical and subclinical axillary adenopathy cases associated with the Pfizer-BioNTech and Moderna vaccines are increasingly reported. However, only one study on axillary adenopathy due to the CoronaVac vaccine is published. To present the incidence, severity, and ultrasonographic findings of axillary adenopathy that developed in healthcare professionals in Turkey after they were vaccinated with CoronaVac against coronavirus disease-19. A prospective study. In Turkey, the first dose of the CoronaVac vaccine for coronavirus disease-19 was administered to healthcare professionals on January 14, 2021, and the second dose on February 11, 2021. This study covered the period from January 21, 2021 (1 week after the first dose), and April 15, 2021 (9 weeks after the second dose). Individuals who had a history of COVID-19 more than 3 weeks after vaccine doses, systemic disease, and diagnosis and treatment history of breast cancer were excluded. The axillary lymph nodes of the vaccinated and contralateral arms were evaluated in 101 volunteer healthcare professionals using axillary ultrasonography. A significant difference was found in the cortical thicknesses of the lymph nodes between the vaccinated and contralateral axilla after both the first (*p < 0.01) and second (*p < 0.01) doses. Accordingly, the rates of subclinical lymphatic hyperplasia on the vaccinated side were 25.7% (n = 26/101) after the first and 31.1% (n = 28/90) after the second dose. Lymph nodes with pathological appearance based on a reduced echogenic hilum with marked cortical thickening were found only in 2.2%. Among the 39 cases in which antibodies (immunoglobulin G and immunoglobulin M) were measured, the antibody level was classified as <10 and ≥10. No statistically significant difference was found in the cortical thickness of the axillary lymph nodes between patients with high antibody levels (≥10) and those with low antibody levels (<10) (p > 0.05). In this study, clinical signs of axillary lymph node hyperplasia were not detected after vaccination with CoronaVac. Mild and diffuse thickening of the CoronaVac vaccine-induced lymph nodes was more common than pathological and palpable lymph nodes.
28 March 2023 in Clinical Neurology and Neurosurgery
30 April 2023 in Düzce Tıp Fakültesi Dergisi
Aim: This study aimed to demonstrate the feasibility of the percutaneous endobiliary radiofrequency ablation (ERFA) method, which is used to increase stent patency in malignant biliary strictures. Material and Methods: A total of 25 patients, 9 (36%) female and 16 (64%) male, who developed malignant biliary stenosis secondary to various advanced tumors and underwent ERFA and metallic stenting after percutaneous biliary drainage were retrospectively evaluated. The types of malignancies causing obstruction and the follow-up after the procedure were evaluated to demonstrate the median survival and stent patency values of the patients. Stent patency and survival rates were calculated using the Kaplan-Meier method. Results: The results of the study demonstrated that 17 (68%) out of these 25 patients displayed a significant decrease in their first-week postoperative bilirubin values, with a reduction of greater than 50% compared to the pre-biliary drainage values. The study determined that this treatment approach's overall clinical success rate was 68%. Stent occlusion developed within 180 days in 8 (32%) out of the 25 patients who underwent ERFA and metallic stenting. Additionally, 18 (%72) patients died as a result of malignancy progression. The mortality rates at post-treatment 30 and 180 days were determined to be 24% and 72%, respectively. The median survival and stent patency times were 65 and 70 days, respectively. Conclusion: Percutaneous ERFA and metallic stenting have the potential to improve survival and stent patency, especially in selected patient groups with distal biliary stenosis. Randomized controlled studies are needed to confirm these results.